Trial Profile

A Single and Repeat Dosing Study of the Safety, Drug Exposure and Clinical Activity of R-2487 in Patients with Rheumatoid Arthritis

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs R-2487 (Primary)
Indications Rheumatoid arthritis
Focus Adverse reactions
Sponsors Rise Therapeutics

Most Recent Events

06 Jan 2025 According to the Rise Therapeutics media release, the company has completed dose escalation enrollment stages and will now initiate the planned dose expansion stages, enrolling additional patients at fixed doses in this study.
29 Jan 2024 According to a Rise Therapeutics media release, first patient has been enrolled in this trial.
19 Oct 2023 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com